NFKBIA
NFKBIA (NF-kappa-B inhibitor alpha) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Multiple myeloma and Diffuse large B-cell lymphoma.
Overview
Inhibits the activity of dimeric NF-kappa-B/REL complexes by trapping REL (RELA/p65 and NFKB1/p50) dimers in the cytoplasm by masking their nuclear localisation signals. On cellular stimulation by immune and pro-inflammatory responses, becomes phosphorylated promoting ubiquitination and degradation, enabling the dimeric RELA to translocate to the nucleus and activate transcription.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant. IntOGen calls it a driver in 5 cohorts (0 activating, 5 loss-of-function), covering Diffuse Large B-Cell Lymphoma, NOS, Malignant Lymphoma, Non-Hodgkin Lymphoma, Plasma Cell Myeloma.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · NFKBIA (NF-kappa-B inhibitor alpha) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Multiple myeloma and Diffuse large B-cell lymphoma.
- 1 · What it is
NFKBIA (NF-kappa-B inhibitor alpha) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Multiple myeloma and Diffuse large B-cell lymphoma.
- 2 · What goes wrong in cancer
Inhibits the activity of dimeric NF-kappa-B/REL complexes by trapping REL (RELA/p65 and NFKB1/p50) dimers in the cytoplasm by masking their nuclear localisation signals.
- 3 · How drugs use it
No product in this corpus aims at NFKBIA yet. Because the protein is lost rather than overactive, drugs either restore its function or exploit the weakness its loss leaves (synthetic lethality).
External identifiers
Sources: HGNC HGNC:7797 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P25963 (protein name, function text, keywords and locations (REST API)); CIViC gene NFKBIA (1 evidence items, 0 assertions, 1 variants; diseases: Diffuse Large B-cell Lymphoma (GraphQL API, CC0)); IntOGen NFKBIA (driver in 5 cohorts (Act 0, LoF 5); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Inhibits the activity of dimeric NF-kappa-B/REL complexes by trapping REL (RELA/p65 and NFKB1/p50) dimers in the cytoplasm by masking their nuclear localisation signals. On cellular stimulation by immune and pro-inflammatory responses, becomes phosphorylated promoting ubiquitination and degradation, enabling the dimeric RELA to translocate to the nucleus and activate transcription. Location: Cytoplasm; Nucleus (UniProt). Locus 14q13.2 (HGNC).
- Non-Hodgkin lymphoma: IntOGen driver in 2 cohorts (MLYM, NHL)
- Multiple myeloma: IntOGen driver in 1 cohort (PCM)
- Diffuse large B-cell lymphoma: CIViC evidence names this disease; IntOGen driver in 2 cohorts (DLBCLNOS)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it a loss-of-function (LoF) driver in 5 cohorts; CIViC holds 1 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"NFKBIA" OR ABSTRACT:"NFKBIA" OR TITLE:"NFKB inhibitor alpha" OR ABSTRACT:"NFKB inhibitor alpha" OR TITLE:"NF-kappa-B inhibitor alpha" OR ABSTRACT:"NF-kappa-B inhibitor alpha" OR TITLE:"MAD-3" OR ABSTRACT:"MAD-3" OR TITLE:"IkappaBalpha" OR ABSTRACT:"IkappaBalpha" OR TITLE:"NFKBI" OR ABSTRACT:"NFKBI") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about NFKBIA, not a curated reading list.